Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Depaus

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
British Journal of Haematology|November 29, 2018
Therapeutic recommendations for early stage Hodgkin lymphomasJulien Depaus, Anne Delcourt, Marc André
Cureus|June 30, 2026
Recurrent Severe Infections During Teclistamab Therapy in a Kidney Transplant Recipient With Relapsed Multiple Myeloma: A Case ReportMaxime Rousseau, Anne Deweweire, Julien Depaus, et al.
Case Reports in Oncology|February 1, 2024
Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case ReportPierre-Yves Sansen, Luc Montfort, Anne Nanquette, et al.
European Journal of Case Reports in Internal Medicine|September 9, 2024
An Unusual Case of HHV-8 Negative, Idiopathic, Multicentric Castleman Disease Following Chronic Lymphocytic LeukaemiaPierre-Yves Sansen, Hélène Vellemans, Julien Depaus, et al.
Case Reports in Oncology|October 30, 2023
Cryptosporidiosis, an Uncommon Complication after Allogeneic Stem-Cell TransplantationEdwige Boulet, Carlos Graux, Anne Sonet, et al.
Cancer Medicine|July 26, 2020
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trialsMarc P E André, Patrice Carde, Simonetta Viviani, et al.
Nature Medicine|August 15, 2023
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial resultsAlexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, et al.
Blood|January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS TrialAurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
British Journal of Haematology|November 29, 2018
Therapeutic recommendations for early stage Hodgkin lymphomasJulien Depaus, Anne Delcourt, Marc André
Cureus|June 30, 2026
Recurrent Severe Infections During Teclistamab Therapy in a Kidney Transplant Recipient With Relapsed Multiple Myeloma: A Case ReportMaxime Rousseau, Anne Deweweire, Julien Depaus, et al.
Case Reports in Oncology|February 1, 2024
Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case ReportPierre-Yves Sansen, Luc Montfort, Anne Nanquette, et al.
European Journal of Case Reports in Internal Medicine|September 9, 2024
An Unusual Case of HHV-8 Negative, Idiopathic, Multicentric Castleman Disease Following Chronic Lymphocytic LeukaemiaPierre-Yves Sansen, Hélène Vellemans, Julien Depaus, et al.
Case Reports in Oncology|October 30, 2023
Cryptosporidiosis, an Uncommon Complication after Allogeneic Stem-Cell TransplantationEdwige Boulet, Carlos Graux, Anne Sonet, et al.
Cancer Medicine|July 26, 2020
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trialsMarc P E André, Patrice Carde, Simonetta Viviani, et al.
Nature Medicine|August 15, 2023
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial resultsAlexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, et al.
Blood|January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS TrialAurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Pageof 1